<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03567941</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_16_07</org_study_id>
    <nct_id>NCT03567941</nct_id>
  </id_info>
  <brief_title>To Evaluate the Relative Abuse Potential of Hydrocodone Bitartrate and Acetaminophen</brief_title>
  <official_title>A Randomized, Double-Blind, Double-Dummy, Active- and Placebo-Controlled, 4-Way Crossover Study to Evaluate the Relative Abuse Potential of Hydrocodone Bitartrate and Acetaminophen 6 × 10/325 mg Tablets Compared to NORCO® 6 × 10/325 mg Tablets and Placebo in Non-Dependent, Recreational Opioid Users When Administered Orally Under Fed and Fasted Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of abuse potential in recreational abusers of Hydrocodone Bitartrate and
      Acetaminophen versus NORCO®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 29, 2017</start_date>
  <completion_date type="Actual">October 31, 2018</completion_date>
  <primary_completion_date type="Actual">October 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Liking</measure>
    <time_frame>15 weeks</time_frame>
    <description>Visual analog scale on score from 0 to 100</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrocodon bitartrate-acetaminophen arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrocodon bitartrate-acetaminophen arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet orally administered under fasting</description>
    <arm_group_label>Hydrocodon bitartrate-acetaminophen arm 1</arm_group_label>
    <arm_group_label>Hydrocodon bitartrate-acetaminophen arm 2</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocodon bitartrate-acetaminophen arm 1</intervention_name>
    <description>Tablet orally administered under fasted conditions</description>
    <arm_group_label>Hydrocodon bitartrate-acetaminophen arm 1</arm_group_label>
    <arm_group_label>Hydrocodon bitartrate-acetaminophen arm 2</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocodon bitartrate-acetaminophen arm 2</intervention_name>
    <description>Tablet orally administered under fed conditions</description>
    <arm_group_label>Hydrocodon bitartrate-acetaminophen arm 1</arm_group_label>
    <arm_group_label>Hydrocodon bitartrate-acetaminophen arm 2</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference</intervention_name>
    <description>Tablet orally administered under fasted conditions</description>
    <arm_group_label>Hydrocodon bitartrate-acetaminophen arm 1</arm_group_label>
    <arm_group_label>Hydrocodon bitartrate-acetaminophen arm 2</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female subjects 18 to 55 years of age.

          2. Opioid users who have used opioids for recreational purposes and or is an avid opioid
             user.

        Exclusion Criteria:

          1. Substance or alcohol dependence (excluding nicotine and caffeine) within the past 2
             years.

          2. Heavy smoker and/or is unable to abstain from smoking or unable to abstain from the
             use of prohibited nicotine containing products for at least 6 hours during the
             in-clinic periods.

          3. Difficulty swallowing large number of pills.

          4. Subjects who have had a tattoo or body piercing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SPARC Site 1</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5V 2T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>June 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Hydrocodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

